FAQ: Nutriband Inc. Secures Patent in Macao for AVERSA Abuse-Deterrent Technology

What is Nutriband Inc.’s AVERSA technology?

AVERSA is an abuse-deterrent transdermal technology developed by Nutriband Inc. designed to reduce abuse, diversion, and accidental exposure of transdermal drugs like opioids.

Why is the patent in Macao significant for Nutriband Inc.?

The patent in Macao expands Nutriband’s global IP portfolio to cover 46 countries and both SARs of China, enhancing the company’s ability to protect and commercialize its AVERSA technology worldwide.

How does AVERSA technology work?

AVERSA technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential, though the specific mechanisms are not detailed in the provided content.

Who is Nutriband Inc. partnering with to develop AVERSA Fentanyl?

Nutriband Inc. is advancing the development of AVERSA Fentanyl with its partner Kindeva Drug Delivery.

What are the projected U.S. sales for the AVERSA Fentanyl patch?

The AVERSA Fentanyl patch has projected peak U.S. sales of $80 million to $200 million.

Where can I find more information about Nutriband Inc.?

More information about Nutriband Inc. can be found on their website at www.Nutriband.com.

When was the AVERSA technology patent granted in Macao?

The patent for AVERSA technology was granted on Feb. 11 and recorded in Macao’s Official Bulletin on Mar. 5.

What is the title of the patent granted to Nutriband Inc. in Macao?

The patent is titled ‘Abuse and Misuse Deterrent Transdermal Systems.’

Where can I view the full press release about Nutriband Inc.’s patent in Macao?

The full press release can be viewed at https://ibn.fm/dfThG.